Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.81EUR
16 Jan 2017
Change (% chg)

€-1.26 (-1.61%)
Prev Close
€78.07
Open
€77.51
Day's High
€78.16
Day's Low
€76.71
Volume
1,901,516
Avg. Vol
2,833,720
52-wk High
€79.07
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.85
Market Cap(Mil.): €100,868.20
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.93
Yield (%): 3.75

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.22 30.00 30.92
EPS (TTM): 3.22 -- --
ROI: -- 15.39 14.82
ROE: -- 16.57 16.24

BRIEF-Sanofi buys 87,298 shares of Regeneron's common stock on Jan 11

* Sanofi reports open market purchase of 87,298 shares of Regeneron Pharmaceuticals Inc's common stock on Jan 11 - SEC filing Source text: http://bit.ly/2iR2AXn Further company coverage:

14 Jan 2017

CORRECTED-Regeneron CEO says Amgen not putting patients first in patent dispute

Jan 9 Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

10 Jan 2017

BRIEF-Regeneron says Sanofi plant used to fill drugs now deemed acceptable

* Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable

10 Jan 2017

BRIEF-MannKind says receives $30.6 million from Sanofi

* MannKind receives $30.6 million from Sanofi Source text for Eikon: Further company coverage:

09 Jan 2017

BRIEF-Sanofi and Immunext enter into agreement to develop treatments for autoimmune diseases

* Sanofi and Immunext enter into agreement to develop treatments for autoimmune diseases

09 Jan 2017

PRESS DIGEST - Wall Street Journal - Jan 6

Jan 6 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

06 Jan 2017

Regeneron, Sanofi to appeal U.S. judge's ban on cholesterol drug sales

Regeneron Pharmaceuticals Inc and Sanofi SA said on Thursday they would appeal the U.S. District Court ruling which banned the two companies from selling their cholesterol drug, Praluent, on grounds of patent infringement.

06 Jan 2017

Sanofi, Regeneron lose bid to overturn Amgen win in patent case

A federal judge on Tuesday refused to throw out a court verdict upholding two Amgen Inc patents related to the company's cholesterol drug, a defeat for Sanofi SA and Regeneron Pharmaceuticals Inc, which make a rival drug.

04 Jan 2017

EXCLUSIVE: J&J discussing breaking up Actelion in an acquisition - sources

Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development assets, people familiar with the matter said on Thursday.

29 Dec 2016

Exclusive: J&J discussing breaking up Actelion in an acquisition - sources

Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development assets, people familiar with the matter said on Thursday.

29 Dec 2016

Earnings vs. Estimates